Advanced Biomed Inc. (ADVB)

NASDAQ: ADVB · Real-Time Price · USD
1.070
-0.580 (-35.15%)
At close: May 8, 2025, 4:00 PM
1.060
-0.010 (-0.93%)
After-hours: May 8, 2025, 6:14 PM EDT
-35.15%
Market Cap 23.15M
Revenue (ttm) n/a
Net Income (ttm) -3.04M
Shares Out 21.64M
EPS (ttm) -0.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 855,154
Open 1.550
Previous Close 1.650
Day's Range 1.020 - 1.550
52-Week Range 1.010 - 4.100
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About ADVB

Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan. The company’s devices include A+Pre, a fully automated sample preparation system that enables pre-concentration of diluted blood samples; AC-1000, a rare cell device to solve the problem of detection of hypercoagulable state samples of tumor patients; A+SCDrop, a circulating tumor cells (CTCs) single-cell capture device; and A+Cel... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 6, 2025
Employees 40
Stock Exchange NASDAQ
Ticker Symbol ADVB
Full Company Profile

Financial Performance

Financial Statements

News

Sonoro Energy, Advanced BioCatalytics, and NexTier Energy Launch Strategic Collaboration to Advance Heavy Oil Recovery from Carbonate Reservoirs in the Middle East

May 5, 2025 – TheNewswire - Calgary, Alberta – Sonoro Energy Ltd. (“Sonoro” or the “Company” (TSX Venture: SNV) is pleased to announce that Sonoro, Advanced BioCatalytics Corporation, and NexTier Ener...

3 days ago - TheNewswire

Advanced Biomed Inc. Announces Closing Of US$6.56 Million Initial Public Offering

Tainan, Taiwan, March 07, 2025 (GLOBE NEWSWIRE) -- Advanced Biomed Inc. (the "Company") (NASDAQ: ADVB), a biotechnology company focused on early screening and detection, diagnosis and staging, and tre...

2 months ago - GlobeNewsWire

IPO Update: Advanced Biomed Finalizes $112 Million U.S. IPO Plan

Advanced Biomed has filed proposed terms for a $112 million U.S. IPO. The firm is developing a portfolio of cancer screening technologies for the Chinese market. ADVB has no revenue history, significa...

1 year ago - Seeking Alpha

Advanced Biomed sets IPO terms, which could value the biotech at up to $625 million

Advanced Biomed Inc. ADVB, has set terms for its initial public offering, in which the Taiwan-based biotechnology company focused on treating cancer is looking to raise up to $125 million. The company...

1 year ago - Market Watch

Advanced Biomed Begins $150 Million U.S. IPO Rollout

Advanced Biomed has filed to raise $150 million in a U.S. IPO, although the final amount may vary. The Taiwan-based firm is developing various diagnostic test technologies for cancer and is focused on...

2 years ago - Seeking Alpha

Advanced Biomed IPO Registration Document (S-1)

Advanced Biomed has filed to go public with an IPO on the NASDAQ.

2 years ago - SEC